Q2 2026 EPS Estimates for Quest Diagnostics Incorporated (NYSE:DGX) Increased by Analyst

Quest Diagnostics Incorporated (NYSE:DGX) – Zacks Research raised their Q2 2026 earnings per share estimates for Quest Diagnostics in a research report issued on Tuesday, September 24th. Zacks Research analyst M. Mondal now forecasts that the medical research company will post earnings of $2.59 per share for the quarter, up from their previous estimate of $2.58. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.89 per share.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.31 by $0.04. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.39 billion. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the firm earned $2.30 EPS.

DGX has been the topic of several other reports. Citigroup upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $165.00 in a research report on Wednesday, July 10th. Barclays raised their price target on Quest Diagnostics from $144.00 to $154.00 and gave the company an “equal weight” rating in a report on Tuesday, August 27th. Piper Sandler upped their price objective on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “neutral” rating in a research note on Monday, July 29th. StockNews.com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 23rd. Finally, Evercore ISI initiated coverage on Quest Diagnostics in a research note on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price target for the company. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Hold” and an average price target of $154.33.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $154.71 on Friday. The company has a market capitalization of $17.19 billion, a P/E ratio of 20.91, a P/E/G ratio of 2.80 and a beta of 0.89. Quest Diagnostics has a 1-year low of $119.59 and a 1-year high of $159.36. The firm’s 50 day simple moving average is $151.11 and its two-hundred day simple moving average is $141.63. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be given a dividend of $0.75 per share. The ex-dividend date is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.94%. Quest Diagnostics’s dividend payout ratio is currently 40.38%.

Insider Activity at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 1,990 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the sale, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Mark E. Delaney sold 420 shares of the business’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total transaction of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Karthik Kuppusamy sold 1,990 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total value of $304,987.40. Following the completion of the sale, the senior vice president now owns 11,459 shares of the company’s stock, valued at $1,756,206.34. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Quest Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Van Lanschot Kempen Investment Management N.V. purchased a new position in shares of Quest Diagnostics during the 2nd quarter worth about $48,783,000. M&G Plc purchased a new position in shares of Quest Diagnostics during the first quarter valued at approximately $46,432,000. Vanguard Group Inc. grew its stake in shares of Quest Diagnostics by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock valued at $1,853,151,000 after buying an additional 345,754 shares during the last quarter. Pathstone Holdings LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter worth approximately $46,342,000. Finally, Wedge Capital Management L L P NC lifted its stake in shares of Quest Diagnostics by 601.7% during the 2nd quarter. Wedge Capital Management L L P NC now owns 277,561 shares of the medical research company’s stock worth $37,993,000 after acquiring an additional 238,007 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.